Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model

Journal of Pharmacology and Experimental Therapeutics

Volumn 327, Issue 2, 2008, Pages 592-599

  Fujita, Tomoe ^a,d   Yasuda, Shuichi ^a   Kamata, Yuji ^b   Fujita, Kazumi ^a   Ohtani, Yoshio ^c   Kumagai, Yuji ^a,d   Majima, Masataka ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c Syounan Sakura Clinic   (Japan)

^d KITASATO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A; INTERLEUKIN 6; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PUROMYCIN AMINONUCLEOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; ENZYME REGULATION; INFERIOR CAVA VEIN; INTESTINE; LIVER; MALE; NEPHROSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PORTAL VEIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DISEASE MODELS, ANIMAL; DOWN-REGULATION; INTERLEUKIN-6; INTESTINES; LIVER; MALE; NEPHROSIS; P-GLYCOPROTEIN; PUROMYCIN AMINONUCLEOSIDE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 54349120790     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.142091     Document Type: Article

References (26)

1. Aitken AE, Richardson TA, and Morgan ET (2006) Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46:123-149.
2. Berg-Candolfi M, Candolfi E, and Benet LZ (1996) Suppression of intestinal and hepatic cytochrome P4503A in murine Toxoplasma infection. Effects of N-acetylcysteine and N(G)-monomethyl-L-arginine on the hepatic suppression. Xenobiotica 26:381-394.
3. Cakaloglu Y, Marinos G, Marsden J, Peters TJ, Williams R, and Tredger JM (1993) Localization of cyclosporin A absorption in rat small bowel and the effect of bile. Clin Sci (Lond) 84:675-679.
4. Chen YL, Le Vraux V, Leneveu A, Dreyfus F, Stheneur A, Florentin I, De Sousa M, Giroud JP, Flouvat B, and Chauvelot-Moachon L (1994) Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 55:649-660.
5. Cherrington NJ, Slitt AL, Li N, and Klaassen CD (2004) Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab Dispos 32:734-741.
6. Fradette C, Batonga J, Teng S, Piquette-Miller M, and du Souich P (2007) Animal models of acute moderate hypoxia are associated with a down-regulation of CYP1A1, 1A2, 2B4, 2C5, and 2C16 and up-regulation of CYP3A6 and P-glycoprotein in liver. Drug Metab Dispos 35:765-771.
7. Goumenos DS, Kalliakmani P, Tsakas S, Savidaki I, and Vlachojannis JG (2006) Cyclosporin-A in the treatment of nephrotic syndrome: the importance of monitoring C0 (trough) and C2 (two hours after its administration) blood levels. Med Chem 2:391-393.
8. Jin M, Shimada T, Yokogawa K, Nomura M, Ishizaki J, Piao Y, Kato Y, Tsuji A, and Miyamoto K (2006) Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice. Biochem Pharmacol 72:1042-1050.
9. Kim S, Kim CH, and Vaziri ND (2005) Upregulation of hepatic LDL receptor-related protein in nephrotic syndrome: response to statin therapy. Am J Physiol Endocrinol Metab 288:E813-E817.
10. Koltun M, Nikolovski J, Strong K, Nikolic-Paterson D, and Comper WD (2005) Mechanism of hypoalbuminemia in rodents. Am J Physiol Heart Circ Physiol 288:H1604-H1610.
11. Leblond F, Guévin C, Demers C, Pellerin I, Gascon-Barré M, and Pichette V (2001) Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12:326-332.
12. Leblond FA, Petrucci M, Dubé P, Bernier G, Bonnardeaux A, and Pichette V (2002) Downregulation of intestinal cytochrome p450 in chronic renal failure. J Am Soc Nephrol 13:1579-1585.
13. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, et al. (1997) Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248-260.
14. Maezono S, Sugimoto K, Sakamoto K, Ohmori M, Hishikawa S, Mizuta K, Kawarasaki H, Watanabe Y, and Fujimura A (2005) Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein. Pediatr Transplant 9:315-323.
15. Mahnke A, Strotkamp D, Roos PH, Hanstein WG, Chabot GG, and Nef P (1997) Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver. Arch Biochem Biophys 337:62-68.
16. Masuda S, Goto M, Kiuchi T, Uemoto S, Kodawara T, Saito H, Tanaka K, and Inui K (2003) Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation. Liver Transpl 9:1108-1113.
17. Murthy JN, Yatscoff RW, and Soldin SJ (1998) Cyclosporine metabolite cross-reactivity in different cyclosporine assays. Clin Biochem 31:159-163.
18. Nishigaki J, Suzuki Y, and Shigematsu A (1998) A novel method for measuring the hepatic first-pass effect and metabolic rate of L-3,4-dihydroxyphenylalanine (DOPA), diazepam and inulin in rat liver. Biol Pharm Bull 21:735-740.
19. Piquette-Miller M, Pak A, Kim H, Anari R, and Shahzamani A (1998) Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. Pharm Res 15:706-711.
20. Projean D, Dautrey S, Vu HK, Groblewski T, Brazier JL, and Ducharme J (2005) Selective downregulation of hepatic cytochrome P450 expression and activity in a rat model of inflammatory pain. Pharm Res 22:62-70.
21. Renton KW (2001) Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 92:147-163.
22. Renton KW (2005) Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol 1:629-640.
23. Sewer MB and Morgan ET (1998) Down-regulation of the expression of three major rat liver cytochrome P450S by endotoxin in vivo occurs independently of nitric oxide production. J Pharmacol Exp Ther 287:352-358.
24. Siewert E, Bort R, Kluge R, Heinrich PC, Castell J, and Jover R (2000) Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology 32:49-55.
25. Takara K, Ohnishi N, Horibe S, and Yokoyama T (2003) Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAS in small intestine. Drug Metab Dispos 31:1235-1239.
26. Vos TA, Hooiveld GJ, Koning H, Childs S, Meijer DK, Moshage H, Jansen PL, and Müller M (1998) Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology 28:1637-1644.